- Home
- TOPP vs TENX Comparison
TOPP vs TENX Comparison
Compare TOPP & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOPP
- TENX
- Stock Information
- Founded
- TOPP 2014
- TENX 1967
- Country
- TOPP United States
- TENX United States
- Employees
- TOPP N/A
- TENX N/A
- Industry
- TOPP
- TENX Biotechnology: Pharmaceutical Preparations
- Sector
- TOPP
- TENX Health Care
- Exchange
- TOPP NYSE
- TENX Nasdaq
- Market Cap
- TOPP 26.6M
- TENX 21.6M
- IPO Year
- TOPP 2025
- TENX N/A
- Fundamental
- Price
- TOPP $1.79
- TENX $6.06
- Analyst Decision
- TOPP
- TENX Strong Buy
- Analyst Count
- TOPP 0
- TENX 3
- Target Price
- TOPP N/A
- TENX $16.00
- AVG Volume (30 Days)
- TOPP 31.1K
- TENX 11.9K
- Earning Date
- TOPP 05-15-2025
- TENX 05-14-2025
- Dividend Yield
- TOPP N/A
- TENX N/A
- EPS Growth
- TOPP N/A
- TENX N/A
- EPS
- TOPP N/A
- TENX N/A
- Revenue
- TOPP $16,117,227.00
- TENX N/A
- Revenue This Year
- TOPP N/A
- TENX N/A
- Revenue Next Year
- TOPP N/A
- TENX N/A
- P/E Ratio
- TOPP N/A
- TENX N/A
- Revenue Growth
- TOPP 0.44
- TENX N/A
- 52 Week Low
- TOPP $0.97
- TENX $2.77
- 52 Week High
- TOPP $4.50
- TENX $7.89
- Technical
- Relative Strength Index (RSI)
- TOPP N/A
- TENX 55.80
- Support Level
- TOPP N/A
- TENX $5.60
- Resistance Level
- TOPP N/A
- TENX $6.31
- Average True Range (ATR)
- TOPP 0.00
- TENX 0.27
- MACD
- TOPP 0.00
- TENX -0.01
- Stochastic Oscillator
- TOPP 0.00
- TENX 63.31
About TOPP TOPPOINT HOLDINGS INC
Toppoint Holdings Inc is a truckload services and solutions provider focused on the recycling export supply chain. The company operates in one operating segment where it derives its revenues from the delivery of truckload services.
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.